Social Capital Suvretta Holdings Corp. III in its $2.64 billion business combination with ProKidney LP

On January 18, 2022, Social Capital Suvretta Holdings Corp. III, a publicly traded special purpose acquisition company led by Chamath Palihapitiya, announced its entry into a business combination agreement with ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapeutics.  The transaction values the combined company at a $2.64 billion post-money equity value and includes a $575 million PIPE financing led by Social Capital.  Wachtell, Lipton, Rosen & Katz served as legal advisor to Social Capital Suvretta Holdings Corp. III.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.